Literature DB >> 19382043

[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].

H Neeff1, F Makowiec, J Harder, V Gumpp, A Klock, R Thimme, O Drognitz, U T Hopt.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth-leading cause of cancer death world-wide. Although less frequent in Western Europe, its incidence is increasing in this region. Causes involved in the pathogenesis of HCC are, besides viral hepatitis, metabolic and nutritional factors (alcohol, diabetes, obesity). The therapeutic management depends strongly on the initial extent of disease and includes hepatic resection, liver transplantation and local ablation. In this context, we present our results on liver resection for HCC and a discussion of the current literature about (potentially curative) treatment for HCC. PATIENTS: From 1999 until 2008 93 patients [83 % male, median age 64 (range: 39-94) years] underwent hepatic resection for HCC. Postoperative follow-up was available in 85 patients [median follow-up: 1.2 (0.25-8) years].
RESULTS: In contrast to data, especially from Asia, a viral hepatitis as the origin of HCC was found in only 28 % of the patients in our series. Half of the patients had proven liver cirrhosis. The median number of intrahepatic tumours was one (1-11), median size of the largest tumour was 55 mm (5-250 mm). 58 % of the HCC were removed by atypical or segmental resection, 42 % of the patients underwent hemihepatectomy or extended -hemihepatectomy. Tumor-free resection margins were -achieved in 95 %. Total postoperative morbidity was 61 %. A reoperation for complications was -necessary in 10 %. Hospital mortality was 8.6 % in the entire study period but decreased from 14.9 % in 1999-2004 to 2.2 % in 2005 to 2008 (p = 0.03). Actuarial survival was 81 % after 1 year, 58 % after 3 years and 26 % after 5 years. The T-stage could be identified tendentially as a prognostic factor influencing survival.
CONCLUSION: With the proper selection of patients, liver resection for HCC may be performed with a curative intention (i. e., free resection margins) in over 90 %. Although it decreased during the study period peri-operative mortality was higher than after resection of other hepatic tumours. Long-term survival in our series was comparable to reports from other European centres.

Entities:  

Mesh:

Year:  2009        PMID: 19382043     DOI: 10.1055/s-0028-1098881

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  5 in total

1.  Comparison of two different transection techniques in liver surgery-an experimental study in a porcine model.

Authors:  T Gehrig; G Manzini; H Fonouni; M Golriz; R Hafezi; N Rahbari; K Brand; U Hinz; B P Müller-Stich; C N Gutt; A Mehrabi
Journal:  Langenbecks Arch Surg       Date:  2013-06-20       Impact factor: 3.445

2.  Animal and cellular models of hepatocellular carcinoma bone metastasis: establishment and characterisation.

Authors:  Rui Hou; Yu-Wei Wang; Hui-Fang Liang; Zhan-Guo Zhang; Zhi-Min Liu; Bin-Hao Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-28       Impact factor: 4.553

3.  Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma.

Authors:  Peter Gassmann; Tilmann Spieker; Joerg Haier; Fabian Schmidt; Wolf Arif Mardin; Norbert Senninger
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

4.  Perioperative mortality after non-hepatic general surgery in patients with liver cirrhosis: an analysis of 138 operations in the 2000s using Child and MELD scores.

Authors:  Hannes Neeff; Dimitri Mariaskin; Hans-Christian Spangenberg; Ulrich T Hopt; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2011-01       Impact factor: 3.452

5.  Impact of multiple liver resections prior to salvage liver transplantation on survival in patients with recurrent HCC.

Authors:  Zhenhua Hu; Qijun Zhang; Jie Zhou; Zhiwei Li; Jie Xiang; Lin Zhou; Jian Wu; Min Zhang; Shusen Zheng
Journal:  BMJ Open       Date:  2015-09-09       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.